Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide)
Esophageal Varices With Bleeding
Explore 6 assets in Esophageal Varices With Bleeding →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
General Hospital of Shenyang Military Region
Modality
protein_peptide
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03130127CT.gov Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis | — | Unknown | — | — | — |
NCT03846180CT.gov Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Varices With Bleeding
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) (this asset) | General Hospital of Shenyang Military Region | N/A | D · 30 |
| Apsolol | West China Hospital | P4 | BBB |
| Normal Human Serum Albumin | King George's Medical University | P4 | BB |
| Carvedilol | West China Hospital | P4 | BB |
| Nadolol | National Science and Technology Council, Taiwan | P4 | BB |
| Phytonadione, (E)-(±)- | Tanta University | P4 | BB |
| Midodrine | Hospital Clinic of Barcelona | P4 | BB |
| Tranexamic Acid | Tanta University | P4 | BB |
| Simvastatin | Juan A. Arnaiz | P3 | BB |
+7 more in the Esophageal Varices With Bleeding cohort
Other indications for Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatorenal Syndrome | — | P4 | A · 84 |
| Cirrhosis Of Liver | — | P4 | BBB · 77 |
| Esophageal Varices | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) in Esophageal Varices With Bleeding. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gly-gly-gly-cys-tyr-phe-gln-asn-cys-pro-lys-gly-nh2-4-9-disulfide-esophageal-varices-with-bleeding
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →